SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-009369
Filing Date
2024-06-20
Accepted
2024-06-20 17:03:57
Documents
15
Period of Report
2024-06-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrxp-20240613x8k.htm   iXBRL 8-K 46924
2 EX-99.1 nrxp-20240613xex99d1.htm EX-99.1 12830
  Complete submission text file 0001558370-24-009369.txt   227668

Data Files

Seq Description Document Type Size
3 EX-101.SCH nrxp-20240613.xsd EX-101.SCH 4489
4 EX-101.DEF nrxp-20240613_def.xml EX-101.DEF 14196
5 EX-101.LAB nrxp-20240613_lab.xml EX-101.LAB 20670
6 EX-101.PRE nrxp-20240613_pre.xml EX-101.PRE 15410
18 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20240613x8k_htm.xml XML 7262
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 241057335
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)